Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bradley Pharmaceuticals has entered into a collaboration and license agreement to commercialize MediGene AG's genital warts ointment Polyphenon E in the US.
Subscribe to our email newsletter
Genital warts appear as benign but contagious skin tumors in the genital and anal areas. This disease is one of the most common and fastest spreading venereal diseases worldwide. It is estimated that approximately 14 million people in the US are infected with the strains of human papilloma virus that cause genital warts, making the US the largest market for this indication.
Bradley and MediGene together will decide whether to develop Polyphenon E for other dermatological indications based on a joint clinical development plan.
“Bradley Pharmaceuticals is excited to enter this collaboration with MediGene. This agreement marks Bradley’s expansion into new specialty healthcare markets, and is an important milestone for the company,” stated Bradley president and CEO, Daniel Glassman.